机译:Crizotinib充当ATP结合与变构抑制的ATP抑制剂,并且对天然BCR-ABL1和其电阻和化合物突变体BCR-Abl1(T315i)和BCR-Abl1(T315i-E255K)是有源的
Cardiff Univ Div Canc &
Genet Med Sch Dept Hematol Heath Pk Cardiff CF14 4XN Wales;
Goethe Univ Dept Internal Med 2 Frankfurt Germany;
Migal Galilee Technol Ctr Dept Nutr &
Nat Prod POB 831 IL-11016 Kiryat Shmona Israel;
Bnai Zion MC Oncol Dept Haifa Israel;
Clin Goethe Univ Dept Internal Med 1 Frankfurt Germany;
Bar Ilan Univ Azrieli Fac Med Ziv Med Ctr Hematol Inst Zfat Israel;
Bar Ilan Univ Azrieli Fac Med Ziv Med Ctr Hematol Inst Zfat Israel;
Cardiff Univ Div Canc &
Genet Med Sch Dept Hematol Heath Pk Cardiff CF14 4XN Wales;
Cardiff Univ Div Canc &
Genet Med Sch Dept Hematol Heath Pk Cardiff CF14 4XN Wales;
Ecole Polytech Fed Lausanne Swiss Inst Expt Canc Res Sch Life Sci Lausanne Switzerland;
Clin Goethe Univ Dept Internal Med 1 Frankfurt Germany;
Cardiff Univ Div Canc &
Genet Med Sch Dept Hematol Heath Pk Cardiff CF14 4XN Wales;
Migal Galilee Technol Ctr Dept Nutr &
Nat Prod POB 831 IL-11016 Kiryat Shmona Israel;
Crizotinib; Philadelphia chromosome-positive leukemia; BCR-ABL1; TKI resistance; Allosteric inhibition; Compound mutations;
机译:构象控制开关控制抑制剂DCC-2036对BCR-ABL1酪氨酸激酶(包括Gatekeeper T315I突变体)的抑制作用。
机译:ASCIMINIB的疗效和安全性是靶向Myristoyl结合位点的特异性变革BCR-ABL1抑制剂,患有T315i突变的慢性骨髓性白血病(CML)患者
机译:ASCIMINIB是一种特异的血糖BCR-ABL1抑制剂,慢性骨髓白血病患者在1期试验中携带T315i突变
机译:T315I突变BCR-ABL1酪氨酸激酶的新型抑制剂通过基于片段的药物设计治疗慢性粒细胞白血病
机译:所述BCR-aBL1酪氨酸激酶包括网守T315I突变体的构象控制的抑制由开关控制抑制剂DCC-2036
机译:开关控制抑制剂DCC-2036对BCR-ABL1酪氨酸激酶的构象控制抑制,包括Gatekeeper T315I突变体